Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Affimed NV AFMD

Healthcare Biotechnology
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1... see more

Recent & Breaking News (NDAQ:AFMD)

Affimed Announces Addition to NASDAQ Biotechnology Index

GlobeNewswire December 17, 2019

Affimed Reports Third Quarter 2019 Financial Results and Recent Operational Progress

GlobeNewswire November 19, 2019

Affimed Announces Third Quarter 2019 Financial Results and Corporate Update Conference Call on November 19, 2019

GlobeNewswire November 14, 2019

Affimed to Present at the Jefferies 2019 London Healthcare Conference

GlobeNewswire November 14, 2019

Affimed Announces Closing of Public Offering of Common Shares and Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire November 13, 2019

Affimed Announces Pricing of Public Offering of Common Shares

GlobeNewswire November 8, 2019

Affimed Announces Proposed Public Offering of Common Shares

GlobeNewswire November 7, 2019

Affimed Announces FDA Clearance of IND to Commence First-in-Human Phase 1/2a Study of AFM24 for the Treatment of EGFR-Expressing Cancers

GlobeNewswire November 7, 2019

Affimed Highlights Progress on NK Cell Engager Collaboration with Genentech

GlobeNewswire November 7, 2019

Affimed Reports Progress on Key Clinical Development Programs

GlobeNewswire October 15, 2019

Affimed to Participate in Investor Conferences in September

GlobeNewswire August 28, 2019

Affimed Reports Second Quarter 2019 Financial and Operational Results

GlobeNewswire August 7, 2019

Affimed Announces Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 7, 2019

GlobeNewswire July 31, 2019

Affimed Added to the Russell 2000®, 3000® and Microcap Indexes

GlobeNewswire July 1, 2019

Affimed Announces Clinical Data Update on Lead Product Candidate AFM13 in CD30+ lymphoma at ICML 2019

GlobeNewswire June 24, 2019

Affimed to Present Data on AFM13 at the 15th International Conference on Malignant Lymphoma in Lugano, Switzerland

GlobeNewswire June 12, 2019

Affimed Announces Annual General Meeting of Shareholders

GlobeNewswire June 4, 2019

Icosagen and AbCheck Announce Five-year Licensing Agreement Granting AbCheck Access to Icosagen's Patented Mammalian Expression Technology

GlobeNewswire June 3, 2019

Affimed to Present at the Jefferies 2019 Healthcare Conference

GlobeNewswire May 29, 2019

Affimed Announces R&D Strategy to Focus on Innate Immunity Portfolio; Reports First Quarter 2019 Financial Results and Operational Progress

GlobeNewswire May 22, 2019